In this white paper, our COO and Managing Director, Christian Schroeter, delves into the different approaches for restoring immune tolerance. From Topas’ technology leveraging the liver’s natural tolerogenic power to diverse methods across the tolerization field, Dr. Schroeter analyzes the complex manufacturing challenges these novel therapies face and how there are a range of efforts seeking to create solutions for patients with autoimmune and antigen-driven conditions.
